생명제약 기술 라이선스 경상로열티 추정에 관한 연구
A Study on the Estimation of Running Royalty of Biopharmaceutical Technologies in Licensing Agreements
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Bioharmaceutical technologies have consistently been areas in which large licensing agreements have been negotiated. However, there are very limited informations in the open literature on how its running royalty rates are determined and no specific methods are yet provided. The purpose of this study is to suggest an appropriate method for the estimation of running royalty of bioharmaceutical technology in licensing agreements. Here distribution of risk-adjusted operating margins are obtained by simulation using statistics of success rates in the stage of clinical trials and profit margins. Three factors based on technology, business and license legal terms are considered and combined as licensing competitiveness level. Finally, reasonable running royalty is estimated by combining simulated distribution and licensing competitiveness level. This suggested method is expected to practically useful for licensor to establish an appropriate running royalty rate for licensing.
Abstract
Bioharmaceutical technologies have consistently been areas in which large licensing agreements have been negotiated. However, there are very limited informations in the open literature on how its running royalty rates are determined and no specific methods are yet provided. The purpose of this study is to suggest an appropriate method for the estimation of running royalty of bioharmaceutical technology in licensing agreements. Here distribution of risk-adjusted operating margins are obtained by simulation using statistics of success rates in the stage of clinical trials and profit margins. Three factors based on technology, business and license legal terms are considered and combined as licensing competitiveness level. Finally, reasonable running royalty is estimated by combining simulated distribution and licensing competitiveness level. This suggested method is expected to practically useful for licensor to establish an appropriate running royalty rate for licensing.
참고문헌 (28)
- 김석관, "혁신의 분업구조와 우리나라 제약산업의 발전전략", 의약품정책연구, 1(1), pp.97~106 (2006)
- 국내 제약산업 연구개발 동향분석, "권영관", 보건산업기술동향, 57~64 (2006)
- 박현우, "제약분야 기술거래의 로열티 결정구조와 요인", 기술혁신학회지, 10(3), pp.406~430 (2007), 한국기술혁신학회
- 서상혁, "기술마케팅 핸드북, 산업자료센타", ~ (2005)
- 발명의 사업성평가 매뉴얼 제작 연구 보고서, "성웅현", 한국발명진흥회, 15~24 (2007)
- 성웅현, "블랙-숄즈모형을 이용한 기술 R&D 투자가치 구간추정 연구", 기술혁신학회지, 8(1), pp.29~50 (2005), 한국기술혁신학회
- 생명공학분야 로열티 결정모형 사전연구, "성웅현", 생명공학정책연구센터, 43~48 (2008)
- 성웅현, "특허인용 수명분석을 이용한 기술의 경제적 수명 추정에 대한 연구", 지식경영연구, 8(1), pp.49~63 (2007), 한국지식경영학회
- 기술이전실무 사례연구, "이형복", 특허청, 45~61 (2002)
- Arora Ashish, "Specialized supply firms, property rights and firm boundaries", Industrial and Corporate Change, 13, pp.451~475 (2004)
- AUS Consultants, "Annual review of industry royalty rates, Licensing Economics Review", pp.8~ (2003), AUS
- Barry, D., "Scrip's Pharmaceutical Company League Tables" (2003), Informa Healthcare
- Degnan S. A., "A survey of licensed royalties", pp.91~96 (1997), LES Nouvelles
- DiMasi, J., "Risks in new drug development : approval sucess rates for investigational drugs", Clinical Pharmacological Therapy, 69, pp.297~307 (2001)
- DiMasi, Joseph A., "The price of innovation : new estimates of drug development costs", Journal of Health Economics, 22, pp.151~185 (2003)
- Monte Carlo-The Future of Phamaceutical Forecating, Wood Mackenzie Consulting-Issue I, "Holzinger, Erik", ~ (2003)
- Ernst, H., "The use of patent data for technological forecasting : The diffusion of cnc-technology in the machine tool industry", Small Business Economics, 9, pp.361~381 (1997)
- Hardy, Charles T., "Quantitative Deal Valuation Optimization in the Biotechnology and Pharmaceutical Industries", Journal of Biolaw and Business, 7(1), pp.1~10 (2004)
- Kisken, Jane, "Business model and investment trends in the biotechnology industry in Europe", Journal of Commercial Biotechnology, 8(3), pp.191~199 (2002)
- Finch sharon, "Royalty rates: current issues and trends", Journal of commercial biotechnology, 7 (2001)
- Lou K,, "The 'not invented here' myth", Nature Review Drug Discovery, 5, pp.121~130 (2006)
- McGavock, "Factors affecting royalties rates", pp.107~ (1992), Les Nouvelles
- Norland, Rick, "First principles background to financing canada's biotechnology companies", pp.1~37 (2004), Thorington Corporation
- Papadapoulos, S,, "Quantifying the dream: Valuation approaches in biotechnology", Nature Biotechnology, 16, pp.55~56 (1998)
- Rodgers, M,, "Valuation and design of pharmaceutical r&d licensing data", American Institute of Chemical Engineers, 51(1), pp.198~209 (2005)
- Smith, G. V,, "Valuation of Intellectual Property and Intangible Assets, 3rd ed" (2001), John Wiely and Sons, Inc.
- Wada, Tetsuo, "Running royalty and patent citations: The role of measurement cost in unilateral patent licensing, National Institute of Science and Technology Policy", discussion paper, 35, pp.1~26 (2004)
- Zaharoff, Howard G,, "Setting values and royalty rates for medical and life science business", pp.1~4 (2004), Morse Marnes Brown Pendleton